ASCO 2026: Telisotuzumab Adizutecan Shows Promising Activity in Platinum-Resistant Ovarian Cancer

Promising results were observed with telisotuzumab adizutecan (TMAb-A) in patients with platinum-resistant ovarian cancer, with higher response rates seen in tumors with increased c-MET expression. At ASCO 2026, Gini Fleming, Professor of Medicine and Medical Director of Gynecologic Oncology at the University of Chicago, presents the basket trial findings and discusses the next steps in the clinical development of TMAb-A.